In patent clash with Xarelto-maker Bayer, Mylan’s PTAB win called into question
The US Court of Appeals for the Federal Circuit this morning seemed far more interested in the third ground presented by appellant Bayer Pharma Aktiengesellschaft than the two which came before....To view the full article, register now.
Already a subscriber? Click here to view full article